Guangzhou Wondfo Biotech Co.,Ltd
300482.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.84B
Close$
$4.77
70.5% downside
Current Fair Value
70.5% downsideOvervalued by 70.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.84 Billion |
|---|---|
| Enterprise Value | $8.29 Billion |
| Dividend Yield | $0.22 (1.31%) |
| Earnings per Share | $-0.13 |
| Beta | 0.83 |
| Outstanding Shares | 466,657,160 |
Return
| Return on Equity | -2.38% |
|---|---|
| Return on Assets | -1.92% |
| Return on Invested Capital | -2.73% |
Valuation & Multiples
| P/E Ratio | -62.39 |
|---|---|
| PEG | -0.1 |
| Price to Sales | 4.04 |
| Price to Book Ratio | 1.47 |
| Enterprise Value to Revenue | 4.41 |
| Enterprise Value to EBIT | -54.12 |
| Enterprise Value to Net Income | -64 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$457.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$459.75 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Guangzhou Wondfo Biotech Co.,Ltd
2,443 employees
CEO: Zhongxiong Peng Guangzhou Wondfo Biotech Co.,Ltd operates as a biotechnology enterprise, specializing in the research, development, production, and distribution of point-of-care testing (POCT) products. The company additionally provides rapid diagnostic...